Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone

International Journal of Immunopharmacology

Volumn 20, Issue 12, 1998, Pages 685-695

  Cain, W C ^a   Stuart, R W ^a   Lefkowitz, D L ^a   Starnes, J D ^b   Margolin, S ^c   Lefkowitz, S S ^b  

^a TEXAS TECH UNIVERSITY   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c Marnac Inc   (United States)

Author keywords

IL 6 Inhibition of TNF; M ; Pirfenidone; Tumor necrosis factor

Indexed keywords

PIRFENIDONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; FIBROSIS; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPTIC SHOCK;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; GALACTOSAMINE; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED C57BL; PYRIDONES; SHOCK, SEPTIC; THIOGLYCOLATES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031771673     PISSN: 01920561     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0192-0561(98)00042-3     Document Type: Article

References (24)

1. Adams, D. O., and Marino, P. A. (1984). Activation of mononuclear phagocytes for destruction of tumor cells as a model for study of macrophage development. In Gorden (Ed.), Contem. Topics in Heme. and Oncol. (pp. 69-136). New York: Plenum Press.
2. Beil W. J., Weller P. F., Peppercorn M. A., Galli S. J., Dvorak A. M. J. Leukoc. Biol. 58:1995;284-298.
3. Beutler B., Cerami A. Nature. 320:1986;584-588.
4. Blackwell T. S., Christman J. W. British J. of Anesthesia. 77:1996;110-117.
5. Brennan F. M., Feldman M. Cur. Opin. in Immunol. 8:1996;872-877.
6. Carswell E. A., Old L J., Kassel R.L., Green S., Fiore N., Williamson B. Proc. Natl. Acad. Sci. 72:1975;3666-3670.
7. Feldmann M., Brennan F. M., Maini R. N. Annu. Rev. Immunol. 14:1996;397-440.
8. Geldemian M. P., Lefkowitz D. L., Lefkowitz S. S., Bollen A., Moguilevsky N. Pro. Soc. Exp. Biol. Med. 217:1998;81-88.
9. Iyer S. N., Schiedt M. J., Margolin S. B., Hyde D. M., Giri S. Am. J. Respir. Crit. Care Med. 151:1995;200.
10. Iyer S. N., Gurujeyalakshmi G., Giri S. N. FASEB J. 10:1996;300.
11. Lefkowitz, D. L., Lefkowitz, S. S., Wei, R. Q., and Everse, J. (1986). Activation of macrophages with oxidative enzymes. In G. DiSabato and J. Everse (Eds.), Methods in Enzymology (pp. 537-548). Orlando, FL: Academic Press Inc.
12. Lefkowitz D. L., Lincoln J. A., Lefkowitz S. S., Bollen A., Moguilevsky N. Immunol. Cell Biol. 75:1997;136-141.
13. Lurton J. M. Am. J. Respir. Crit. Care Med. 153:1996;403.
14. Malek-Ahmadi P. Neurosci. and Biobehav. Rev. 20:1996;359-365.
15. Molloy R. G., Mannick J. A., Rodrick M. L. Br. J. Surg. 80:1993;289-297.
16. Owens T., Sriram S. Neurol. Clin. 13:1995;51-73.
17. Sekut L., Champion B. R., Page K., Menius J. A., Connolly K. M. Clin. Exp. Immunol. 99:1995;461-466.
18. Sell, S., Berkower, I., and Max, E. E. (1996). The reticuloendothelial systemblood and tissue clearance. In Immunology, Immunopathology, and Immunity (pp. 275-288). Stamford, CT: Appleton and Lange.
19. Semmler J., Wachtel H., Endres S. Int. J. Immunopharm. 15:1993;409-413.
20. Shimizu F., Fukagawa M., Kurokawa K., Yamauchi S., Margolin S. B. J. Am. Soc. Nephr. 7:1996;1765.
21. Spriggs, D. R., and Yates, S. W. (1992). Medical uses of TNF and TNF inhibitors: cancer chemotherapy: experiences with TNF administration in humans. In B. Beutler (Ed.), Tumor necrosis factors: the molecules and their emerging role in medicine (pp. 383-406). New York: Raven Press, NY.
22. Stahl P. D. Am. J. Respir. Cell Mol. Biol. 2:1990;317-318.
23. Suga H., Teraoka S., Ota K. Exper. Toxic. Pathol. 47:1995;287-291.
24. Vallyathan V., Giri S. N., Leonard S., Margolin S. B. Am. J. Respir. Crit. Care. Med. 153:1996;738.